Similar articles

• Lafora body disease: a case of progressive myoclonic epilepsy.

  Kaur R, Balaini N, Sharma S, Sharma SK. Kaur R, et al. BMJ Case Rep. 2020 Dec 22;13(12):e236971. doi: 10.1136/bcr-2020-236971. BMJ Case Rep. 2020. PMID: 33370974 Free PMC article.
• Typical progression of myoclonic epilepsy of the Lafora type: a case report.

  Striano P, Zara F, Turnbull J, Girard JM, Ackerley CA, Cervasio M, De Rosa G, Del Basso-De Caro ML, Striano S, Minassian BA. Striano P, et al. Nat Clin Pract Neurol. 2008 Feb;4(2):106-11. doi: 10.1038/ncpneuro0706. Nat Clin Pract Neurol. 2008. PMID: 18256682
• Fixation-sensitive myoclonus in Lafora disease.

  Kumada S, Kubota M, Hayashi M, Uchiyama A, Kurata K, Kagamihara Y. Kumada S, et al. Neurology. 2006 May 23;66(10):1574-6. doi: 10.1212/01.wnl.0000216147.12172.39. Neurology. 2006. PMID: 16717223
• Lafora disease with novel autopsy findings: a case report with endocrine involvement and literature review.

  Corcia L, Hohensee S, Olivero A, Wong J. Corcia L, et al. Pediatr Neurol. 2014 Nov;51(5):713-6. doi: 10.1016/j.pediatrneurol.2014.07.034. Epub 2014 Aug 7. Pediatr Neurol. 2014. PMID: 25217339 Review.
• Some treatments cause seizure aggravation in idiopathic epilepsies (especially absence epilepsy).

  Somerville ER. Somerville ER. Epilepsia. 2009 Sep;50 Suppl 8:31-6. doi: 10.1111/j.1528-1167.2009.02233.x. Epilepsia. 2009. PMID: 19702731 Review.